Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PaxMedica, Inc. Common Stock (PXMD)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
303 South Broadway 10591
Tarrytown, NY, US
Tarrytown, NY, US
CEO
Howard J. Weisman
Website
paxmedica.com
IPO
2022-08-26
CIK 1811623 ISIN US70424C2035
Description
PaxMedica, Inc. is a biopharmaceutical company currently in the clinical development phase, dedicated to advancing anti-purinergic drug therapies (APTs). These innovative treatments are specifically designed to address complex neurological disorders presenting with stubborn and persistent symptoms. The company's primary investigative drug is PAX-101, an intravenous (IV) form of suramin, which is being explored for a variety of conditions. These include autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, post-COVID-19 syndrome (commonly known as "long COVID"), and human African trypanosomiasis. Furthermore, PaxMedica is also developing PAX-102, an intranasal version of suramin, intended for various neurological applications. The company, which was incorporated in 2018 and has its headquarters in Tarrytown, New York, previously operated as Purinix Pharmaceuticals LLC before rebranding to PaxMedica, Inc. in April 2020. It functions as a subsidiary of Tardimed Sciences LLC.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1.9K
Beta
-0.57
Float Shares
10.69M
Free Float %
8.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +40.00% | +16.67% | +600.00% | +600.00% | +600.00% | -100.00% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
DCF (Unlevered)
2.37
+338,196.3%
DCF (Levered)
2.83
+404,559.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-176.29
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+61.7% ★ Q2'24: +90.4% (vs Q2'23)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q2'24: +562.4% (vs Q2'23)
-
Share dilution Biotechnology: -3.4%+223.4% Q2'24: +789.5% (vs Q2'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q2'24: 0.00× (vs Q2'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
|---|---|---|
| Revenue |
—
|
—
est.
|
| EBITDA |
-16.15M
|
—
est.
|
| EBIT |
-18.28M
|
—
est.
|
| Net Income |
-18.29M
est: -9.06M (-101.9%)
|
-1.81M
est.
|
| SGA |
12.23M
|
—
est.
|
| EPS |
-11.00
est: -5.45 (-101.9%)
|
-1.09
est.
|
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
7
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Michael Derby | 7.70M | 63.40% | 7.70M | — | 7.70M | — | IN | — | 2022-09-09 | ↗ |
| 2 | TardiMed Sciences LLC | 7.34M | 62.30% | 7.34M | — | 7.34M | — | OO | — | 2022-09-09 | ↗ |
| 3 | Blue Cane Partners, LLC | 1.18M | 9.90% | 1.18M | — | 1.18M | — | OO | Delaware | 2022-09-09 | ↗ |
| 4 | Craig Kesselman | 1.18M | 9.90% | 1.18M | — | 1.18M | — | IN | Delaware | 2022-09-09 | ↗ |
| 5 | Jeff Easton | 450.0K | 9.90% | 450.0K | — | 450.0K | — | IN | Delaware | 2023-11-29 | ↗ |
| 6 | Lind Global Fund II LP | 450.0K | 9.90% | 450.0K | — | 450.0K | — | PN | Delaware | 2023-11-29 | ↗ |
| 7 | Lind Global Partners II LLC | 450.0K | 9.90% | 450.0K | — | 450.0K | — | OO | Delaware | 2023-11-29 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
14
Shares acquired
—
Shares disposed
16.4K
Cash buys
—
Cash sales
4.00
Net activity
-16,361
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-12 | Weisman Howard J. | Director / Officer | F-InKind | D | Common Stock | 2,927 | 0.69 | 2.0K | 34,748 | — | ↗ |
| 2024-03-12 | Sheldon Stephen | Officer | F-InKind | D | Common Stock | 3,356 | 0.69 | 2.3K | 10,137 | — | ↗ |
| 2024-03-12 | Rome Zachary | Director | F-InKind | D | Common Stock | 4,904 | 0.69 | 3.4K | 10,244 | — | ↗ |
| 2024-03-12 | LaRochelle Karen | Director | F-InKind | D | Common Stock | 604 | 0.69 | 416.76 | 2,225 | — | ↗ |
| 2024-03-12 | Hough David W. | Officer | F-InKind | D | Common Stock | 1,452 | 0.69 | 1.0K | 5,905 | — | ↗ |
| 2024-03-12 | Coelho John F | Director | F-InKind | D | Common Stock | 207 | 0.69 | 142.83 | 4,408 | — | ↗ |
| 2024-03-12 | CASAMENTO CHARLES J | Director | F-InKind | D | Common Stock | 992 | 0.69 | 684.48 | 2,386 | — | ↗ |
| 2024-02-21 | Sheldon Stephen | Officer | F-InKind | D | Common Stock | 243 | 0.66 | 160.14 | 13,493 | — | ↗ |
| 2024-02-21 | Hough David W. | Officer | F-InKind | D | Common Stock | 291 | 0.66 | 191.77 | 7,357 | — | ↗ |
| 2024-01-29 | Weisman Howard J. | Director / Officer | S-Sale | D | Common Stock | 372 | 0.47 | 174.84 | 37,675 | — | ↗ |
| 2024-01-29 | Rome Zachary | Director | S-Sale | D | Common Stock | 811 | 0.48 | 389.28 | 15,148 | — | ↗ |
| 2024-01-29 | LaRochelle Karen | Director | S-Sale | D | Common Stock | 78 | 0.48 | 37.44 | 2,829 | — | ↗ |
| 2024-01-29 | Coelho John F | Director | S-Sale | D | Common Stock | 27 | 0.48 | 12.96 | 4,615 | — | ↗ |
| 2024-01-29 | CASAMENTO CHARLES J | Director | F-InKind | D | Common Stock | 97 | 0.76 | 73.72 | 3,378 | — | ↗ |
| 2023-11-27 | Weisman Howard J. | Director / Officer | S-Sale | D | Common Stock | 162 | 1.03 | 166.24 | 38,047 | — | ↗ |
| 2023-11-27 | Rome Zachary | Director | S-Sale | D | Common Stock | 359 | 1.03 | 369.88 | 15,959 | — | ↗ |
| 2023-11-27 | LaRochelle Karen | Director | S-Sale | D | Common Stock | 35 | 1.03 | 35.93 | 2,907 | — | ↗ |
| 2023-11-27 | Derby Michael | 10% Owner | S-Sale | D | Common Stock | 185 | 1.03 | 189.88 | 25,650 | — | ↗ |
| 2023-11-27 | Coelho John F | Director | S-Sale | D | Common Stock | 12 | 1.03 | 12.30 | 4,642 | — | ↗ |
| 2023-11-20 | Sheldon Stephen | Officer | F-InKind | D | Common Stock | 971 | 1.75 | 1.7K | 13,736 | — | ↗ |
| 2023-10-27 | Weisman Howard J. | Director / Officer | S-Sale | D | Common Stock | 8,049 | 0.19 | 1.5K | 649,549 | — | ↗ |
| 2023-10-27 | Rome Zachary | Director | S-Sale | D | Common Stock | 16,301 | 0.18 | 3.0K | 277,390 | — | ↗ |
| 2023-10-27 | LaRochelle Karen | Director | S-Sale | D | Common Stock | 1,679 | 0.19 | 317.33 | 49,994 | — | ↗ |
| 2023-10-27 | Derby Michael | 10% Owner | S-Sale | D | Common Stock | 9,175 | 0.19 | 1.7K | 439,171 | — | ↗ |
| 2023-10-27 | Coelho John F | Director | S-Sale | D | Common Stock | 570 | 0.19 | 108.02 | 79,090 | — | ↗ |
| 2023-10-23 | Hough David W. | Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 130,000 | — | ↗ |
| 2023-10-02 | CASAMENTO CHARLES J | Director | F-InKind | D | Common Stock | 6,536 | 0.29 | 1.9K | 59,047 | — | ↗ |
| 2023-08-30 | Weisman Howard J. | Director / Officer | S-Sale | D | Common Stock | 22,535 | 0.45 | 10.1K | 657,598 | — | ↗ |
| 2023-08-30 | Rome Zachary | Director | S-Sale | D | Common Stock | 4,801 | 0.47 | 2.2K | 293,691 | — | ↗ |
| 2023-08-29 | Weisman Howard J. | Director / Officer | S-Sale | D | Common Stock | 9,596 | 0.48 | 4.7K | 680,133 | — | ↗ |
| 2023-08-29 | Rome Zachary | Director | S-Sale | D | Common Stock | 8,792 | 0.48 | 4.3K | 298,492 | — | ↗ |
| 2023-08-29 | LaRochelle Karen | Director | S-Sale | D | Common Stock | 456 | 0.48 | 221.02 | 51,673 | — | ↗ |
| 2023-08-29 | Derby Michael | 10% Owner | S-Sale | D | Common Stock | 6,540 | 0.48 | 3.2K | 448,346 | — | ↗ |
| 2023-08-29 | Coelho John F | Director | S-Sale | D | Common Stock | 23 | 0.49 | 11.18 | 79,660 | — | ↗ |
| 2023-08-28 | Weisman Howard J. | Director / Officer | S-Sale | D | Common Stock | 12,000 | 0.49 | 5.9K | 689,729 | — | ↗ |
| 2023-08-28 | Rome Zachary | Director | S-Sale | D | Common Stock | 12,000 | 0.49 | 5.9K | 307,284 | — | ↗ |
| 2023-08-28 | LaRochelle Karen | Director | S-Sale | D | Common Stock | 2,000 | 0.50 | 1.0K | 52,129 | — | ↗ |
| 2023-08-28 | Derby Michael | 10% Owner | S-Sale | D | Common Stock | 7,000 | 0.49 | 3.5K | 454,886 | — | ↗ |
| 2023-08-28 | Coelho John F | Director | S-Sale | D | Common Stock | 774 | 0.52 | 403.49 | 79,683 | — | ↗ |
| 2023-08-22 | Rome Zachary | Director | S-Sale | D | Common Stock | 30,000 | 0.54 | 16.2K | 319,284 | — | ↗ |
| 2023-08-21 | Rome Zachary | Director | S-Sale | D | Common Stock | 20,000 | 0.58 | 11.6K | 349,284 | — | ↗ |
| 2023-08-16 | Hough David W. | Officer | — | D | Common Stock | 0 | 0.00 | — | 30,000 | — | ↗ |
| 2023-07-26 | Weisman Howard J. | Director / Officer | F-InKind | D | Common Stock | 9,952 | 0.72 | 7.1K | 701,729 | — | ↗ |
| 2023-07-26 | Rome Zachary | Director / Officer | F-InKind | D | Common Stock | 9,584 | 0.72 | 6.9K | 369,284 | — | ↗ |
| 2023-07-26 | LaRochelle Karen | Director | F-InKind | D | Common Stock | 1,143 | 0.72 | 819.53 | 54,129 | — | ↗ |
| 2023-07-26 | Derby Michael | Director / Officer | F-InKind | D | Common Stock | 6,272 | 0.72 | 4.5K | 461,886 | — | ↗ |
| 2023-07-26 | Coelho John F | Director | F-InKind | D | Common Stock | 389 | 0.72 | 278.91 | 80,457 | — | ↗ |
| 2023-04-26 | Weisman Howard J. | Director / Officer | F-InKind | D | Common Stock | 9,952 | 1.61 | 16.0K | 711,681 | — | ↗ |
| 2023-04-26 | Rome Zachary | Director / Officer | F-InKind | D | Common Stock | 9,584 | 1.61 | 15.4K | 378,868 | — | ↗ |
| 2023-04-26 | LaRochelle Karen | Director | F-InKind | D | Common Stock | 1,143 | 1.61 | 1.8K | 55,272 | — | ↗ |
| 2023-04-26 | Derby Michael | Director / Officer / 10% Owner | F-InKind | D | Common Stock | 6,272 | 1.61 | 10.1K | 468,158 | — | ↗ |
| 2023-04-26 | Coelho John F | Director | F-InKind | D | Common Stock | 389 | 1.61 | 626.29 | 80,846 | — | ↗ |
| 2023-04-13 | Weisman Howard J. | Director / Officer | A-Award | A | Common Stock | 180,000 | 0.00 | — | 721,633 | — | ↗ |
| 2023-04-13 | Sheldon Stephen | Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 250,000 | — | ↗ |
| 2023-04-13 | Rome Zachary | Director / Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 388,452 | — | ↗ |
| 2023-04-13 | LaRochelle Karen | Director | A-Award | A | Common Stock | 14,000 | 0.00 | — | 56,415 | — | ↗ |
| 2023-04-13 | Derby Michael | Director / Officer / 10% Owner | A-Award | A | Common Stock | 150,000 | 0.00 | — | 474,430 | — | ↗ |
| 2023-04-13 | Coelho John F | Director | A-Award | A | Common Stock | 14,000 | 0.00 | — | 81,235 | — | ↗ |
| 2023-04-13 | CASAMENTO CHARLES J | Director | A-Award | A | Common Stock | 14,000 | 0.00 | — | 65,583 | — | ↗ |
| 2023-03-09 | Weisman Howard J. | Director / Officer | S-Sale | D | Common Stock | 3,495 | 1.44 | 5.0K | 541,633 | — | ↗ |
| 2023-03-09 | Rome Zachary | Director / Officer | S-Sale | D | Common Stock | 3,371 | 1.44 | 4.9K | 288,452 | — | ↗ |
| 2023-03-09 | LaRochelle Karen | Director | S-Sale | D | Common Stock | 335 | 1.48 | 495.80 | 42,415 | — | ↗ |
| 2023-03-09 | Derby Michael | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 2,143 | 1.43 | 3.1K | 324,430 | — | ↗ |
| 2023-03-09 | Coelho John F | Director | S-Sale | D | Common Stock | 130 | 1.48 | 192.40 | 67,235 | — | ↗ |
| 2023-03-08 | Weisman Howard J. | Director / Officer | S-Sale | D | Common Stock | 32,397 | 1.46 | 47.3K | 545,128 | — | ↗ |
| 2023-03-08 | Rome Zachary | Director / Officer | S-Sale | D | Common Stock | 30,034 | 1.47 | 44.1K | 291,823 | — | ↗ |
| 2023-03-07 | Weisman Howard J. | Director / Officer | S-Sale | D | Common Stock | 23,551 | 1.53 | 36.0K | 577,525 | — | ↗ |
| 2023-03-07 | Rome Zachary | Director / Officer | S-Sale | D | Common Stock | 23,432 | 1.53 | 35.9K | 321,857 | — | ↗ |
| 2023-03-07 | Derby Michael | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 15,134 | 1.55 | 23.5K | 326,573 | — | ↗ |
| 2023-03-06 | Weisman Howard J. | Director / Officer | S-Sale | D | Common Stock | 13,589 | 1.72 | 23.4K | 601,076 | — | ↗ |
| 2023-03-06 | Rome Zachary | Director / Officer | S-Sale | D | Common Stock | 13,560 | 1.72 | 23.3K | 345,289 | — | ↗ |
| 2023-03-06 | Derby Michael | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 13,828 | 1.72 | 23.8K | 341,707 | — | ↗ |
| 2023-03-03 | Weisman Howard J. | Director / Officer | S-Sale | D | Common Stock | 15,323 | 1.90 | 29.1K | 614,665 | — | ↗ |
| 2023-03-03 | Rome Zachary | Director / Officer | S-Sale | D | Common Stock | 13,199 | 1.89 | 24.9K | 358,849 | — | ↗ |
| 2023-03-03 | LaRochelle Karen | Director | S-Sale | D | Common Stock | 1,097 | 1.90 | 2.1K | 42,750 | — | ↗ |
| 2023-03-03 | Derby Michael | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 18,968 | 1.90 | 36.0K | 355,535 | — | ↗ |
| 2023-03-02 | Weisman Howard J. | Director / Officer | S-Sale | D | Common Stock | 11,679 | 1.94 | 22.7K | 629,988 | — | ↗ |
| 2023-03-02 | Rome Zachary | Director / Officer | S-Sale | D | Common Stock | 12,952 | 1.94 | 25.1K | 372,048 | — | ↗ |
| 2023-03-02 | LaRochelle Karen | Director | S-Sale | D | Common Stock | 7,736 | 1.94 | 15.0K | 43,847 | — | ↗ |
| 2023-03-02 | Derby Michael | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 10,497 | 1.94 | 20.4K | 374,503 | — | ↗ |
| 2023-03-02 | Coelho John F | Director | S-Sale | D | Common Stock | 3,013 | 1.93 | 5.8K | 67,365 | — | ↗ |
| 2022-11-19 | Sheldon Stephen | Officer | A-Award | A | Common Stock | 135,000 | 0.00 | — | 150,000 | — | ↗ |
| 2022-10-01 | CASAMENTO CHARLES J | Director | A-Award | A | Common Stock | 51,583 | 0.00 | — | 51,583 | — | ↗ |
| 2022-08-30 | TardiMed Sciences LLC | Director | P-Purchase | A | Common Stock | 95,000 | 5.25 | 498.8K | 7,336,745 | — | ↗ |
| 2022-08-30 | Derby Michael | Officer | P-Purchase | A | Common Stock | 95,000 | 5.25 | 498.8K | 7,336,745 | — | ↗ |
| 2022-08-12 | Weisman Howard J. | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 601,667 | — | ↗ |
| 2022-08-12 | TardiMed Sciences LLC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 7,241,745 | — | ↗ |
| 2022-08-12 | Sheldon Stephen | Officer | — | — | Common Stock | 0 | 0.00 | — | 18,799 | I | ↗ |
| 2022-08-12 | Rome Zachary | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 361,000 | — | ↗ |
| 2022-08-12 | LaRochelle Karen | Director | — | D | Common Stock | 0 | 0.00 | — | 48,333 | — | ↗ |
| 2022-08-12 | Derby Michael | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 385,000 | — | ↗ |
| 2022-08-12 | Coelho John F | Director | — | — | Common Stock | 0 | 0.00 | — | 67,128 | D | ↗ |
| 2020-11-06 | Sheldon Stephen | Officer | — | — | Warrant (right to buy) | 17,090 | 3.00 | 51.3K | 0 | I | ↗ |
| 2020-11-06 | Coelho John F | Director | — | D | Warrant (right to buy) | 17,086 | 3.00 | 51.3K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
126.26M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | Howard J. Weisman Chief Executive Officer | 478.1K | — | 333.0K | — | 239.1K | — | 1.05M | 31.71% | ↗ |
| 2 | 2023 | Michael Derby Former Executive Chairman | 208.1K | — | 277.5K | — | 103.7K | 41.3K | 671.9K | 41.30% | ↗ |
| 3 | 2023 | Stephen D. Sheldon Chief Financial Officer | 325.0K | — | 185.0K | — | 125.9K | — | 635.9K | 29.10% | ↗ |
| 4 | 2023 | David W. Hough Chief Medical Officer | 75.9K | — | 69.0K | — | 80.6K | 41.3K | 388.6K | 17.76% | ↗ |
| 5 | 2023 | Zachary Rome Former Chief Operating Officer | 64.0K | — | 185.0K | — | 31.9K | 41.3K | 363.5K | 50.90% | ↗ |
| 6 | 2022 | Howard J. Weisman Chief Executive Officer | 400.0K | — | 3.37M | — | 240.0K | — | 4.01M | 84.03% | ↗ |
| 7 | 2022 | Michael Derby Executive Chairman | 325.0K | 162.5K | 2.02M | — | — | — | 2.51M | 80.57% | ↗ |
| 8 | 2022 | Michael Derby Former Executive Chairman | 325.0K | — | 2.02M | — | 162.5K | — | 2.51M | 80.57% | ↗ |
| 9 | 2022 | Zachary Rome Former Chief Operating Officer | 100.0K | — | 2.02M | — | 50.0K | — | 2.17M | 93.09% | ↗ |
| 10 | 2022 | Stephen D. Sheldon Chief Financial Officer | 54.6K | — | 367.1K | — | — | 80.0K | 581.6K | 63.11% | ↗ |
| 11 | 2022 | David W. Hough Chief Medical Officer | 87.5K | — | — | — | — | — | 87.5K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Howard J. Weisman | Chief Executive Officer | 717.2K | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PXMD
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
